US Stock MarketDetailed Quotes

ZVRA Zevra Therapeutics

Watchlist
  • 9.130
  • +0.160+1.78%
Close Nov 21 16:00 ET
  • 9.250
  • +0.120+1.31%
Post 18:56 ET
487.32MMarket Cap-4286P/E (TTM)

About Zevra Therapeutics Company

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Company Profile

SymbolZVRA
Company NameZevra Therapeutics
Listing DateApr 16, 2015
Founded2006
CEOMr. Neil F. McFarlane, M.S.
MarketNASDAQ
Employees69
Fiscal Year Ends12-31
Address1180 Celebration Boulevard,Suite 103
CityCelebration
ProvinceFlorida
CountryUnited States of America
Zip Code34747
Phone1-321-939-3416
Websitehttp://zevra.com

Company Executives

  • Name
  • Position
  • Salary
  • Neil F. McFarlane, M.S.
  • Director, President and Chief Executive Officer
  • 3.45M
  • R. LaDuane Clifton, C.P.A.,M.B.A.
  • Chief Financial Officer, Secretary and Treasurer
  • 2.26M
  • Dr. Sven Guenther, PhD
  • Chief Scientific Officer
  • --
  • Dr. Adrian Quartel, M.D.
  • Chief Medical Officer
  • --
  • Christal M M. Mickle, M.A.
  • Chief Development Officer
  • 1.67M
  • Joshua Schafer, M.B.A.
  • Chief Commercial Officer and Executive Vice President, Business Development
  • 1.82M
  • Timothy J. Sangiovanni
  • Senior Vice President, Corporate Controller and Principal Accounting Officer
  • --
  • Tamara A. Favorito
  • Chairman of the Board
  • 324.39K
  • Dr. Alvin Shih, M.D.
  • Director
  • --
  • Thomas Anderson
  • Independent Director
  • 243.04K
  • Dr. Wendy L. Dixon, PhD
  • Independent Director
  • 274.00K
  • Corey Watton
  • Independent Director
  • 260.67K
  • John B. Bode
  • Independent Director
  • 264.31K
  • Douglas W. Calder
  • Independent Director
  • 258.02K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data